Drugs to suppress cough
- PMID: 15709918
- DOI: 10.1517/13543784.14.1.19
Drugs to suppress cough
Abstract
Cough is an important defensive reflex of the airway and also a common symptom of respiratory disease. Cough after common respiratory virus infection is transient but is more persistent when associated with conditions such as asthma, rhinosinusitis, gastro-oesophageal reflux, chronic obstructive pulmonary disease and lung cancer. Persistent cough may be due to peripheral and/or central sensitisation of cough reflexes initiated by cough receptors, rapidly adapting receptors or nociceptors. Treatment directed at associated conditions such as asthma (with anti-inflammatories) and gastro-oesophageal reflux (with proton-pump inhibitors) improve cough. There remains a need to use drugs that suppress the neural activity of cough (termed nonspecific), as treatments directed at the clinical cause(s) of the underlying cough (termed specific) may not be effective. The most effective indirect antitussives are opioids such as morphine, codeine or pholcodeine, but they produce side effects such as drowsiness, nausea, constipation and physical dependence. Opioids such as kappa- and delta-receptor agonists, non-opioids such as nociceptin, neurokinin and bradykinin receptor antagonists, cannabinoids, vanilloid receptor-1 antagonists, blockers of Na+-dependent channels, and large conductance Ca2+-dependent K+-channel activators of afferent nerves may represent novel antitussives.
Similar articles
-
Current and future prospects for drugs to suppress cough.IDrugs. 2003 Aug;6(8):781-6. IDrugs. 2003. PMID: 12917774 Review.
-
Therapy for cough: active agents.Pulm Pharmacol Ther. 2002;15(3):335-8. doi: 10.1006/pupt.2002.0342. Pulm Pharmacol Ther. 2002. PMID: 12099788 Review.
-
Cough: potential pharmacological developments.Expert Opin Investig Drugs. 2002 Jul;11(7):955-63. doi: 10.1517/13543784.11.7.955. Expert Opin Investig Drugs. 2002. PMID: 12084006 Review.
-
Clinical cough VI: the need for new therapies for cough: disease-specific and symptom-related antitussives.Handb Exp Pharmacol. 2009;(187):343-68. doi: 10.1007/978-3-540-79842-2_18. Handb Exp Pharmacol. 2009. PMID: 18825350 Review.
-
TRPV1 antagonists as potential antitussive agents.Lung. 2008;186 Suppl 1:S59-65. doi: 10.1007/s00408-007-9032-z. Epub 2007 Oct 10. Lung. 2008. PMID: 17926096 Review.
Cited by
-
Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.Clin Pharmacokinet. 2024 Mar;63(3):293-302. doi: 10.1007/s40262-023-01330-7. Epub 2024 Jan 10. Clin Pharmacokinet. 2024. PMID: 38198010 Clinical Trial.
-
The pharmacology of Ro 64-6198, a systemically active, nonpeptide NOP receptor (opiate receptor-like 1, ORL-1) agonist with diverse preclinical therapeutic activity.CNS Drug Rev. 2007 Spring;13(1):107-36. doi: 10.1111/j.1527-3458.2007.00007.x. CNS Drug Rev. 2007. PMID: 17461893 Free PMC article. Review.
-
Multifunctional drugs for head injury.Neurotherapeutics. 2009 Jan;6(1):28-42. doi: 10.1016/j.nurt.2008.10.036. Neurotherapeutics. 2009. PMID: 19110197 Free PMC article. Review.
-
Addictive evaluation of cholic acid-verticinone ester, a potential cough therapeutic agent with agonist action of opioid receptor.Acta Pharmacol Sin. 2009 May;30(5):559-66. doi: 10.1038/aps.2009.43. Acta Pharmacol Sin. 2009. PMID: 19417735 Free PMC article.
-
Inhibition of citric acid- and capsaicin-induced cough by novel TRPV-1 antagonist, V112220, in guinea-pig.Cough. 2007 Dec 23;3:10. doi: 10.1186/1745-9974-3-10. Cough. 2007. PMID: 18154688 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous